Vol 26, No 3 (2019)
Letters to the Editor — Interventional cardiology
Published online: 2019-06-27
Challenging treatment of in-stent restenosis in a coronary bifurcation by implantation of a bioresorbable scaffold under optical coherence tomography guidance
Abstract
Not available
References
- Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention. 2009; 5 Suppl F: F15–F22.
- Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373(9667): 897–910.
- Onuma Y, Serruys PW, Perkins LEL, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010; 122(22): 2288–2300.
- Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv. 2014; 7(1): 89–99.
- Campos CM, Muramatsu T, Iqbal J, et al. Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease. Int J Mol Sci. 2013; 14(12): 24492–24500.
- Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011; 58(15): 1578–1588.
- Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015; 385(9962): 43–54.
- Muramatsu T, Onuma Y, García-García HM, et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. 2013; 6(3): 247–257.
- Ormiston JA, Webber B, Ubod B, et al. Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies. EuroIntervention. 2015; 10(10): 1169–1177.
- Ormiston JA, Webber B, Ubod B, et al. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). EuroIntervention. 2015; 11(1): 60–67.
- Derimay F, Souteyrand G, Motreff P, et al. Sequential proximal optimizing technique in provisional bifurcation stenting with everolimus-eluting bioresorbable vascular scaffold: fractal coronary bifurcation bench for comparative test between absorb and XIENCE xpedition. JACC Cardiovasc Interv. 2016; 9(13): 1397–1406.
- Rivero F, Bastante T, Cuesta J, et al. Treatment of in-stent restenosis with bioresorbable vascular scaffolds: optical coherence tomography insights. Can J Cardiol. 2015; 31(3): 255–259.
- Moscarella E, Ielasi A, Granata F, et al. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience. Circ Cardiovasc Interv. 2016; 9(4): e003148.
- Jamshidi P, Nyffenegger T, Sabti Z, et al. A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. EuroIntervention. 2016; 11(13): 1479–1486.
